HAUGEN JANET BRUTSCHEA 4

What Happened

• Janet Haugen, a director of West Pharmaceutical Services Inc. (WST), received a grant/award of 52 derivative shares on 2026-03-31. The transaction is reported as an "A" (award/grant) at a per-share value of $250.64, for a total reported value of $13,033.
• This was an award (not an open‑market purchase or sale), commonly part of outside director compensation, and does not represent a sale or cash purchase.

Key Details

• Transaction date and price: 2026-03-31; 52 units @ $250.64 each; total value $13,033.
• Transaction code: A (award/grant); classified as a derivative award in the filing.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: References 1,071 restricted stock units (and dividend equivalents) that will vest in full on the date of the next annual shareholder meeting and be distributable under the Deferred Compensation Plan for Outside Directors.
  • F2: States that awards of phantom stock units are to be settled by delivery of shares upon the reporting person's termination as a director.
• Filing timeliness: Reported on 2026-04-01 for a 2026-03-31 transaction — appears to have been filed promptly.

Context

• This was a derivative equity award (RSU/phantom-type units) tied to director compensation rather than an outright purchase; such grants are routine for outside directors and are generally intended as long-term compensation rather than an immediate market signal.
• The filing indicates settlement/vesting mechanics (vesting at next annual meeting or settlement upon termination) rather than immediate share issuance or sale.